Identification and validation of INHBE and P4HA1 as hub genes in non-alcoholic fatty liver disease.
Bioinformatics
Diagnostic biomarkers
Immune microenvironment
Machine learning
Non-alcoholic fatty liver disease (NAFLD)
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
17 Dec 2023
17 Dec 2023
Historique:
received:
25
10
2023
revised:
27
10
2023
accepted:
27
10
2023
medline:
23
11
2023
pubmed:
6
11
2023
entrez:
3
11
2023
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent type of liver disease and a worldwide disease threatening human health. This study aims to identify the novel diagnostic biomarkers of NAFLD by comprehensive bioinformatics and machine learning, and to validate our results in hepatocyte and animal models. We used Gene Expression Omnibus (GEO) databases on NAFLD patients for differential gene expression analyses. Intersections were taken with genes from the key modules of WGCNA and differentially expressed genes (DEGs). Machine learning algorithms like LASSO regression analysis, SVM-RFE, and RandomForest were used to screen hub genes. In addition, a nomogram model and calibration curves were built in order to forecast the probability of NAFLD occurrence. Then, the relationship between hub genes and immune cells was verified using Spearman analysis. Finally, we further verified the expression of key genes by constructing a steatosis hepatocyte model and animal model. Key genes (INHBE and P4HA1) were identified by comprehensive bioinformatics analysis and machine learning. INHBE and P4HA1 were up-regulated and down-regulated in the steatosis hepatocyte model, respectively. Animal experiments also showed that INHBE was up-regulated in the liver of mice fed with high fat diet (HFD). INHBE and P4HA1 are the hub genes of NAFLD. Our findings may contribute to a greater understanding of the occurrence and development of NAFLD and provide potential biomarkers and possible therapeutic targets for future clinical diagnosis and treatment.
Identifiants
pubmed: 37922570
pii: S0006-291X(23)01274-3
doi: 10.1016/j.bbrc.2023.149180
pii:
doi:
Substances chimiques
Biomarkers
0
INHBE protein, human
0
Inhibin-beta Subunits
93443-12-0
P4HA1 protein, human
EC 1.14.11.2
Procollagen-Proline Dioxygenase
EC 1.14.11.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149180Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.